

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7494811

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
JOHNSON MATTHEY PLC	03/16/2021
RECEIVING PARTY DATA	
Name:	ELEUSIS THERAPEUTICS US, INC.
Street Address:	99 WALL STREET #2205
City:	NEW YORK
State/Country:	NEW YORK
Postal Code:	10005
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	17708264
PCT Number:	US2215897
CORRESPONDENCE DATA	
Fax Number:	(617)428-7045
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(617) 428-0200
Email:	patentadmin@clarkelbing.com
Correspondent Name:	CLARK & ELBING LLP
Address Line 1:	101 FEDERAL STREET
Address Line 2:	15TH FLOOR
Address Line 4:	BOSTON, MASSACHUSETTS 02110
ATTORNEY DOCKET NUMBER:	50971-044004; -044WO3
NAME OF SUBMITTER:	JEFFREY J. ELLISON, PH.D.
SIGNATURE:	/Jeffrey J. Ellison, Ph.D./
DATE SIGNED:	08/19/2022
Total Attachments: 2	
source=50971-044002 - Executed Assignment (JM to Eleusis)#page1.tif	
source=50971-044002 - Executed Assignment (JM to Eleusis)#page2.tif	

CONFIRMATION OF ASSIGNMENT

WHEREAS, we, the undersigned, **JOHNSON MATTHEY PLC**, having a place of business at **250 Cambridge Science Park, Milton Road, Cambridge CB4 0WE, United Kingdom** (hereinafter termed "Assignor"), owner of an interest in the right, title and interest in and to certain new and useful improvements disclosed in "**PHARMACEUTICALLY ACCEPTABLE SALTS OF PSILOCIN AND USES THEREOF**", for which an application for United States Letters Patent having U.S. Patent Application No. **63/148,052** was filed **February 10, 2021**, by virtue of a prior assignment from inventors **Claire Wombwell, Daniel Rixson, Peter Haddow, and Carrie Sheard** (hereinafter termed "Inventors"), and in and to all embodiments of the invention, heretofore conceived, made or discovered by said Inventors (all collectively hereinafter termed "said invention"), and in and to any and all patents, inventor's certificates and other forms of protection (hereinafter termed "patents") thereon granted in the United States and foreign countries;

WHEREAS, **ELEUSIS THERAPEUTICS US, INC.**, having a place of business at **99 Wall Street #2205, New York, NY10005, USA** (hereinafter termed "Assignee"), is desirous of acquiring Assignor's entire right, title and interest in and to said application and the invention disclosed therein, and in and to all embodiments of the invention, heretofore conceived, made or discovered by said Inventors (all collectively hereinafter termed "said invention"), and in and to any and all patents, inventor's certificates and other forms of protection (hereinafter termed "patents") thereon granted in the United States and foreign countries.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Assignor to have been received in full from said Assignee:

1. Said Assignor does hereby sell, assign, transfer and convey, and/or confirm prior sale, assignment, transfer, and conveyance, unto said Assignee, Assignor's entire right, title and interest (a) in and to said application and said invention; (b) in and to all rights to apply for foreign patents on said invention pursuant to the International Convention for the Protection of Industrial Property or otherwise; (c) in and to any and all applications filed and any and all patents granted on said invention in the United States or any foreign country, including each and every application filed and each and every patent granted on any application which is a division, substitution, or continuation of any of said applications; and (d) in and to each and every reissue or extensions of any of said patents.

2. Said Assignor hereby covenants and agrees to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right title and interest herein conveyed in the United States and foreign countries. Such cooperation by said Assignor shall include reasonable production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other reasonable assistance to Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any of said applications; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said invention; (d) for filing and prosecuting applications for reissuance of any said patents; (e) for interference or other priority proceedings involving said invention; and (f) for legal proceedings involving said invention and any applications therefore and any patents granted thereon, including without limitation opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that any expense incurred by said Assignor in providing such cooperation shall be paid for by said Assignee.


3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Assignor, their respective heirs, legal representatives and assigns.

The undersigned, whose title is supplied below, is authorized to act on behalf of the assignor.

The undersigned, whose title is supplied below, is authorized to act on behalf of Johnson Matthey PLC.

Date: 16 MAR 2021 Signed: JOHNSON MATTHEY PLC
Craig M Grant
Print Name: CRAIG M GRANT
Print Title: SITE DIRECTOR
Address: 250 Cambridge Science Park, Milton Road, Cambridge CB4 0WE, UK

The undersigned, whose title is supplied below, is authorized to act on behalf of Eleusis Therapeutics US, Inc.

Date: 17-Mar-2021 Signed: ELEUSIS THERAPEUTICS US, INC.

Print Name: Shlomi Raz
Print Title: CEO
Address: 99 WALL STREET #2205, NEW YORK, NY10005, USA